P99. Predictors of new cerebral microbleeds in patients with antiplatelet drug therapy

Cerebral microbleeds (CMBs) are an MRI marker of vascular damage in the brain and are associated with an increased risk for ischemic and especially hemorrhagic stroke. CMBs are known to be more prevalent in patients who take antiplatelet drug therapy, which is commonly used for secondary prevention in patients with ischemic stroke. The aim of the present study was to evaluate the usefulness of susceptibility weighted imaging (SWI) to identify patients at high risk for the development of new CMBs under antiplatelet drug therapy.

Source: Clinical Neurophysiology - July 5, 2015 Category: Neuroscience Authors: K. Menzler, M. Hausdörfer, C. Mayer, M. Belke, A. Gerstner, M. Teepker, R. Werner, H. Hamer, W. Oertel, F. Rosenow, S. Knake Source Type: research